SIRS, In the debate on the use of nucleotide/nucleoside analogues in chronic hepatitis B (CHB), recent guidelines have pointed out that drug-resistant mutations are more frequent with lamivudine, telbivudine or adefovir. For this reason, only entecavir or tenofovir is recommended as first-line monotherapy. 2 As there are no head-to-head comparisons between entecavir and tenofovir, we performed ...

ORI-9020, a novel dinucleotide, evaluated in transgenic mice expressing hepatitis B virus (HBV), significantly reduced liver HBV DNA (P </= 0.001). Levels of HBeAg and HBsAg in serum and of HBcAg in liver were not affected by treatment. A minimal effective dosage was determined to be between 1.6 and 0.5 mg/kg of body weight/day, which was similar to that observed for adefovir dipivoxil.

A new in vitro system based on real-time PCR was developed for evaluation of human herpesvirus 8 susceptibility to antiviral agents. Cidofovir had the greatest inhibitory activity against HHV-8 (50% inhibitory concentration [IC(50)], 0.43 microM) followed by ganciclovir (2.61 microM), adefovir (18.00 microM), acyclovir (31.00 microM), and foscarnet (34.15 microM). The potential therapeutic effi...

crystals ISSN 2073-4352 www.mdpi.com/journal/crystals Supplementary Information Liquid-Assisted Grinding to Prepare a Cocrystal of Adefovir Dipivoxil Thermodynamically Less Stable than Its Neat Phase Sungyup Jung, Insil Choi and Il Won Kim * Department of Chemical Engineering, Soongsil University, Seoul 06978, Korea; E-Mails: [email protected] (S.J.); [email protected] (I.C.) * Author to whom...

The 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines for Management of Chronic Hepatitis B are now posted online at www.aasld.org. This is the fourth version of this guideline; the last version was published in 2007.1 The key changes in the 2009 version are new recommendations for first-line and second-line antiviral agents. Since the last upda...